LAVA Therapeutics NV logo

LVTX

LAVA Therapeutics NV

$2.62

Earnings Summary

Revenue
$1Mn
Net Profits
$-10.56Mn
Net Profit Margins
-1055.5%
PE Ratio
0.29

Highlights

Revenue:

LAVA Therapeutics NV’s revenue jumped 8.58% since last year same period to $1Mn in the Q1 2022. On a quarterly growth basis, LAVA Therapeutics NV has generated -28.62% fall in its revenue since last 3-months.

Net Profits:

LAVA Therapeutics NV’s net profit jumped 36.32% since last year same period to $-10.56Mn in the Q1 2022. On a quarterly growth basis, LAVA Therapeutics NV has generated 32.02% jump in its net profits since last 3-months.

Net Profit Margins:

LAVA Therapeutics NV’s net profit margin jumped 41.35% since last year same period to -1055.5% in the Q1 2022. On a quarterly growth basis, LAVA Therapeutics NV has generated 4.76% jump in its net profit margins since last 3-months.

PE Ratio:

LAVA Therapeutics NV’s price-to-earnings ratio after this Q1 2022 earnings stands at 0.29.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the LAVA Therapeutics NV post its latest quarter earnings

EPS Estimate Current Quarter
-0.61
EPS Estimate Current Year
-0.61

Highlights

EPS Estimate Current Quarter:

LAVA Therapeutics NV’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 25.61% jump from last quarter’s estimates.

EPS Estimate Current Year:

LAVA Therapeutics NV’s earning per share (EPS) estimates for the current year stand at -0.61.

Key Ratios

Key ratios of the LAVA Therapeutics NV post its Q1 2022 earnings

Earning Per Share (EPS)
-0.41
Return on Assets (ROA)
-0.15
Return on Equity (ROE)
-0.3
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

LAVA Therapeutics NV’s earning per share (EPS) jumped 96.08% since last year same period to -0.41 in the Q1 2022. This indicates that the LAVA Therapeutics NV has generated 96.08% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. LAVA Therapeutics NV’s return on assets (ROA) stands at -0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. LAVA Therapeutics NV’s return on equity (ROE) stands at -0.3.

Dividend Per Share (DPS):

LAVA Therapeutics NV declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-0.82
-0.41
50%

Company Information

LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The company’s innovative approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct, selective tumor cell killing. The company’s lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.

Organisation
LAVA Therapeutics NV
Employees
2.02K